EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) has a beta value of 1.74 and has seen 1.24 million shares traded in the last trading session. The company, currently valued at $834.65M, closed the last trade at $16.75 per share which meant it gained $0.59 on the day or 3.65% during that session. The EYPT stock price is -85.01% off its 52-week high price of $30.99 and 66.15% above the 52-week low of $5.67. The 3-month trading volume is 994.74K shares.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) trade information
Sporting 3.65% in the green in last session, the stock has traded in the red over the last five days, when the EYPT stock price touched $16.75 or saw a rise of 10.33%. Year-to-date, EyePoint Pharmaceuticals Inc shares have moved -27.52%, while the 5-day performance has seen it change -5.10%. Over the past 30 days, the shares of EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) have changed -19.51%.
EyePoint Pharmaceuticals Inc (EYPT) estimates and forecasts
Figures show that EyePoint Pharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 164.20% over the past 6 months, with this year growth rate of 4.95%, compared to 12.90% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 26.80% and 26.20% for the next quarter. Revenue growth from the last financial year stood is estimated to be -18.30%.
9 analysts offering their estimates for the company have set an average revenue estimate of $9.92 million for the current quarter. 9 have an estimated revenue figure of $9.82 million for the next quarter concluding in Jun 2024. Year-ago sales stood $7.68 million and $9.11 million respectively for this quarter and the next, and analysts expect sales will grow by 29.10% for the current quarter and 7.90% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 29.57% over the past 5 years.
EYPT Dividends
EyePoint Pharmaceuticals Inc is expected to release its next earnings report in May this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
